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Summary: Galactosyl hydroxylysine and deoxypyridinoline are at present the most promising markers of bone
resorption. Various studies have indeed shown that these two markers discriminate with high accuracy subjects
with different rates of bone turnover and that their accuracies and discriminate power are very similar. The
aim of this paper is to compare the practicality and the reproducibility of the HPLC galactosyl hydroxylysine
and deoxypyridinoline assays.
In summary, this review shows that the galactosyl hydroxylysine and deoxypyridinoline HPLC assays differ
mainly in the need, in using deoxypyridinoline, for an acid hydrolysis and a preextraction of the urine samples.
This implies two major problems for deoxypyridinoline: 1) more time is required due to the cumbersome
preanalytical procedures; and 2) a lower reproducibility. Our data, in fact, show that both the intra-assay
and inter-assay coefficient of variation of the deoxypyridinoline assay are almost 100% higher than those of
the galactosyl hydroxylysine assay.
Introduction . , . , . .the techniques used to measure these two markers
Because of the importance of bone resorption in the with particular emphasis on their practicality and
pathogenesis of bone diseases, there is an increasing their reproducibility.
demand for non-invasive techniques for the rapid and
easy detection of changes in the rate of this process.
Biochemical markers are certainly adequate for this Rationale for the Use of Galactosyl Hydroxylysine and
purpose, and the last decade has seen the development Deoxypyridinoline as Markers for Bone Resorption
of new markers that appear to be specific for bone ^ 4 n . ., 4 , . . . t ._ 4 „ - , t_ Type 1 collagen is the most abundant protein in theresorption. Because type 1 collagen is the most abun- , . . _ . . , . -f r
Λ + . r ' i _ " ιΓ · ' f ^ bone matrix. This unique protein, which accounts fordant protein of the bone matrix, most of the assays . . ΟΛΟ/ Γ . , ίΐ * . j j
r *;. . , . , . almost 80% of the collagens present in the body andfor estimating bone resorption rate measure the uri- u- u · Λ Λ·*- * u · ι · *ι_. · r ,™ * - c .. u f which, m addition to bone, is also present in othernary excretion of different products of collagen break- . . , ' . . .j , « ' . ,· f i t j 7 · j connective tissues, such as skin, is a heterotrumerdown (hydroxyprolme, galactosyl hydroxylysine and Γ , , /τ\ ι · Λ ι · * i j j, -j. f. v formed by two a,(I)-chams and one α-,-chain foldeddeoxypyridinoline). ^ ., . · , , , . τ , ι." ι ι ·together in a triple helix. In bone this molecule is
This review of the present knowledge of galactosyl produced by the osteoblasts and deposited in a highly
hydroxylysine and deoxypyridinoline also compares organized manner in the matrix (for a review on
collagen synthesis see I.e. (1, 2).
') Funding organization: Italian Ministry of the University and Mter the synthesis on the ribosomes, the collagen
Scientific Technol. Res.-MURST chains undergo different post-translational modifica-
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tions both inside and outside the cell. While no dif-
ferences exist in the primary structure of the type 1
collagen deposited in different connective tissues, the
post-translational modifications are, to different ex-
tents, tissue-specific (1).
After the pro-oc-chains have entered the endoplasrnic
cisternae, approximately 100 proline and ten lysine
residues in every chain are hydroxylated by specific
enzymes to hydroxyproline and hydroxylysine. Fur-
thermore, either a galactose or a glucose-galactose is
attached to approximately one third of the hydroxy-
lysine residues by specific transferases, forming gal-
actosyl hydroxylysine and glucosyl-galactosyl
hydroxylysine. As soon as at least 90 proline residues
are converted to hydroxyprolines, two pro-oci(I)-
chains and one pro-a2-chain fold together, an event
which inhibits any further transformation and results
in the formation of type 1 procollagen.
The procollagen molecule is then excreted by the cell
into the extracellular space where the two non-helical
extensions, called N- and C-terminal procollagen pep-
tides, are cleaved off by two specific peptidases. The
new collagen thus formed is then inserted in the ex-
isting matrix and some of the lysines are oxidatively
deaminated by lysyl oxidase. Finally, the oxidized
lysines form reducible and non-reducible crosslinks
within and between the collagen molecules.
Because the products of these post-translational mod-
ifications show a certain tissue specificity, and are
released and excreted in the urine during the collagen
breakdown, they have been proposed as markers of
bone resorption.
Hydroxyproline: The Time-Honoured Marker of Bone
Resorption
Determination of the urinary excretion of hydroxy-
proline is the most commonly used routine clinical
assay for the measurement of bone resorption.
However, hydroxyproline is not specific for bone col-
lagen, since together with proline and alanine it is the
most abundant amino acid (except for glycine) in all
collagen molecules (3). In addition, hydroxyproline is
present in all molecules that have a collagen-like struc-
ture, such as Clq component of complement (4).
Moreover, urinary hydroxyproline excretion cannot
be used to quantify the rate of collagen breakdown,
since about 80% of hydroxyproline released during
this process is metabolized in the liver to H2O and
CO2 (5, 6), and a fraction of the hydroxyproline
(perhaps 10%) that is detectable in urine is derived
from newly synthesized procollagen peptides (7) and
new collagen which is degraded before being deposited
in the matrix (8).
Galactosyl Hydroxylysine and Deoxypyridinoline:
Two New Specific Markers of Bone Resorption
In recent years two different products of collagen
breakdown have been proposed as specific markers
of bone resorption. These molecules are products of
intracellular (galactosyl hydroxylysine) and extracel-
lular (deoxypyridinoline) post-translational collagen
modifications.
Hydroxylysine glycosides are specific for collagen. Al-
though the fraction of hydroxylysine residues that are
glycosylated does not differ in skin or bone (these are
the major sources of type 1 collagen in the human
body) the pattern of hydroxylysine glycosylation is
different in these two tissues. Thus glucosyl-galactosyl
hydroxylysine predominates in the skin, where the
ratio between glucosyl-galactosyl hydroxylysine and
galactosyl hydroxylysine (glucosyl-galactosyl hy-
droxylysine/galactosyl hydroxylysine) is approxi-
mately 2 (9), whereas galactosyl hydroxylysine pre-
dominates in bone, where the glucosyl-galactosyl hy-
droxylysine/galactosyl hydroxylysine ratio is 0.47 (10).
This pattern of glycosylation, moreover, does not
seem to vary in the presence of increased bone turn-
over, since the glucosyl-galactosyl hydroxylysine/gal-
actosyl hydroxylysine ratio in bone collagen is not
altered in Page f 's disease of bone (10). Recently some
concerns have been expressed on the possibility of a
conversion of glucosyl-galactosyl hydroxylysine to
galactosyl hydroxylysine by a kidney oc-glucosidase
demonstrated in the rat (lOb). However, Moro et al.
have recently demonstrated that no a- or ß-glycosi-
dases exist in the human kidney, so that glucosyl-
galactosyl hydroxylysine and galactosyl hydroxylysine
are indeed the final products of collagen degradation
in humans (lOc).
Finally the hydroxylysine glycosides do not undergo
any major liver metabolism and their urinary excre-
tion is not influenced by the diet (10, 11, lib).
The pyridinium crosslink, i. e. pyridinoline, also called
hydroxylysyl-pyridinoline, and deoxypyridinoline,
also named lysyl-pyridinoline, are the most important
non-reducible crosslinks of mature bone collagen.
Pyridinoline is the most abundant of the pyridinium
crosslinks and is present in different connective tis-
sues, including bone, with tte* highest concentration
in cartilage (12). Deoxypyridinoline, on the other
hand, has been detected only in bone and dentine,
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where its concentration is approximately one fourth
of that of pyridinoline (12).
Studies in animals have shown that the amount of
pyridinoline and deoxypyridinoline in bone is not
constant and varies with the extent of mineralization
(14, 15) and the oestrogen status (16), increases with
age (17) and is different in trabecular and cortical
bone (13).
Both crosslinks are released into the bloodstream after
collagen break down, and are then excreted in the
urine where their concentration can be measured.
Because of the different pattern of hydroxylysine gly-
cosylation and because deoxypyridinoline is present
only in bone and dentine and since both these mole-
cules do not undergo any major liver metabolism, the
urinary excretion of galactosyl hydroxylysine and
deoxypyridinoline has been proposed for the estima-
tion of the rate of bone resorption.
In recent years, some clinical studies have compared
the clinical performances of these bone resorption
assays (18 — 20). The results of these studies, which
are summarized in table la and Ib, show that the
clinical performances of galactosyl hydroxylysine and
I deoxypyridinoline are very similar in different patient
• populations. Moreover, in all the clinical conditions
I evaluated so far, there is no indication that one
marker is superior to the other. On the other hand,
some data suggest that the use of the two markers
together may provide better differentiation of the
pathological from the normal condition (19, 20).
Galactosyl Hydroxylysine and Deoxypyridinoline:
A Methodological Comparison
Since more and more data seem to demonstrate a
high similarity in clinical performances of galactosyl
hydroxylysine and deoxypyridinoline, we wanted to
compare the different methodologies used to measure
galactosyl hydroxylysine and deoxypyridinoline and
to evaluate any differences in their practicality and
reproducibility.
Both galactosyl hydroxylysine and deoxypyridinoline
are measured by high performance liquid chromato-
graphy (HPLC) using fluorescence as a signal (12,
21). While deoxypyridinoline is naturally fluorescent,
galactosyl hydroxylysine is not, therefore a derivati-
zation with a fluorescent molecule is needed prior to
the chromatography.
Methods
Preanalytical procedures
Deoxypyridinoline
The pyridinium crosslinks are present in the urine both free
and in the form of peptides of different molecular mass (22).
For this reason an acid hydrolysis is needed prior to the injec-
tion into the HPLC (tab. 2). Due to the very low urine concen-
tration of pyridinoline and deoxypyridinoline (nmol/1) a preex-
traction is also needed.
Galactosyl hydroxylysine
Galactosyl hydroxylysine in urine is all in a free form (22b), so
that no hydrolysis is needed. Furthermore the galactosyl hy-
Tab. 1 a. Similarities in clinical performances between galactosyl hydroxylysine and deoxypyridinoline derived from previous
publications
Galactosyl hydroxylysine, Z score
Deoxypyridinoline, Z score
Galactosyl hydroxylysine, accuracy
Deoxypyridinoline, accuracy
Pagefs
disease
(ii = 12)
3.43
5.5
90%
94%
Children
(n = 4)
7.8
14.3
—
—
Postmenopausal
osteoporosis 1
(n = 13)
3.34
2.87
81%
72%
Postmenopausal
osteoporosis 2
(n = 38)
2.19
2.46
67% + 6%
65% + 7%
Pagefs disease and children were compared with normal adults (n = 22). Osteoporosis 1 were compared with normal premen-
opausal women (n = 11). The correlation between galactosyl hydroxylysine and deoxypyridinoline was r = 0.859, p < 0.001,
n = 51 (18). Osteoporosis 2 were compared with postmenopausal controls (n = 32) (19).
Tab. Ib. Similarities in clinical performances between galactosyl hydroxylysine (mmol/mol of creatinine) and deoxypyridinoline
(μΐϊΐοΐ/mol of creatinine) derived from our unpublished data.
Galactosyl hydroxylysine
Deoxypyridinoline
Baseline
3.85 + 0.9
121.2 ± 55.7
Low dose
4.62 + 1.47
157.9 ± 72.3
Baseline
4.23 + 1.03
100.6 ± 26.9
High dose
5.49 ± 1.89
135.2 ± 30.9
The excretion of the two markers was measured in patients with Ullrich-Turner syndrome before and after treatment with a low
(2 U/m2 · d) (n. = 11) and a high (3 U/m2 · d) (n = 9) dose of somatotropin (growth hormone). All the results are highly significant
p < 0.001.
Eur. J. Clin. Chem. Clin. Biochenx / Vol. 31, 1993 / No. 7
462 Bettica et al.: Galaclosyl hydroxylysine and deoxypyridinoline as bone resorption markers
Tab. 2. Deoxypyridinoline: procedures prior to injection into
HPLC __
- Hydrolysis: overnight in 12 mol/1 HC1 at 108 °C; alter-
natively 2—4 hours in 12 mol/1 HC1 at
125 °C under pressure.
- Preextraclion: on fibrous cellulose (CF1); the samples are
washed with a hydrophobic buffer (t-buta-
nol/acetic acid/water, 4+1 + 1, by vol.) to
separate the crosslinks. The crosslinks are
then eluted with distilled water (time:
4-6 h). Finally, the samples are either lyo-
phylized or freeze-dried (time: overnight).
Total time needed for 20 samples: 36-48 h.
Tab. 3. Galactosyl hydroxylysine: procedures prior to injection
into HPLC
— Derivaiization: all the samples and standards are incubated
with sodium carbonate (30 mmol/1) and
dansyl chloride (10 g/1 in pure acetone) for
30 min at 60 °C. Finally, all the samples and
standards are either centrifuged or filtered
to remove the precipitates.
Total time needed for 20 samples: 2 —3 h.
droxylysine urinary concentration (μιηοΐ/ΐ) is higher than those
of pyridinoline and deoxypyridinoline, so that no preextraction
is needed. On the other hand, as mentioned above, galactosyl
hydroxylysine is not naturally fluorescent, and must therefore
be derivatized with a fluorescent molecule. The molecule used
for this purpose is dansyl chloride (tab. 3). Due to steric hin-
drance, glucosyl-galactosyl hydroxylysine is mainly mono-dan-
sylated, whereas galactosyl hydroxylysine reacts with two dan-
syl chloride molecules (23, 23b).
Analyt ical procedures
Deoxypyridinoline
The two pyridinium crosslinks are separated on a reverse phase
column (C,8) using either a gradient (12) or an isocratic (24)
chromatography.
Both the gradient and isocratic chromatography use an aqueous
buffer with ammonium chloride (0.02 mol/1), EDTA (0.5
mmol/1) and w-heptafluoro butyric acid (0.01 mol/1) as the ion-
pairing agent (solvent A, pH 2.0) and acetonitrile as a hydro-
phobic agent (solvent B).
The pyridinoline and deoxypyridinoline concentrations are cal-
culated by means of external pyridinoline and deoxypyridino-
line standards, which are extracted either from bone or urine.
Galactosyl hydroxylysine
Galactosyl hydroxylysine is separated from the other molecules
on a reverse phase column (C,8) using gradient.chromatography
(21). The aqueous buffer is 0.05 mol/1 acetic acid, 125 ml/1
acetonitrile and 50 ml/l propan-2-ol, pH 6.3 (buffer A) and the
hydrophobic buffer is 0.05 mol/1 acetic acid, 500 ml/1 acetoni-
trile and 10 ml/l propan-2-ol, pH 6.5 (buffer B).
The external standard used to calculate the galactosyl hydroxy-
lysine concentration is L-lysine. L-Lysine was chosen (instead
of ZMysine or hydroxylysine) because, like galactosyl hydroxy-
lysine, it reacts with two molecules of dansyl chloride, therefore
giving only one peak on the chromatogram, corresponding to
the didansyl derivative of L-lysine.
The preanalytical and analytical pi;cicedures for galactosyl hy-
droxylysine and deoxypyridinoline are summarized and com-
pared on table 4a, 4b and 4c.
Tab. 4a. Summary and comparison of galactosyl hydroxylysine
and deoxypyridinoline preanalytical procedures
Preanalytical
procedures
Hydrolysis
Preextraction
Derivatization
Galactosyl
hydroxylysine
no
no
yes
Deoxy-
pyridinoline
yes
yes
no
Tab. 4b. Summary and comparison of galactosyl hydroxylysine
and deoxypyridinoline analytical procedures
Analytical
procedures
System
Detector
Ehition conditions
Galactosyl
hydroxylysine
HPLC
Fluorometer
Gradient
Deoxy-
pyridinoline
HPLC
Fluorometer
Gradient (g) or
isocratic (i)
Elution time of the
Compound (min)
20 7 (g) - 3 (i)
Tab. 4c. Times required for galactosyl hydroxylysine and
deoxypyridinoline analysis
Galactosyl Deoxy-
hydroxylysine pyridinoline
Preanalytical procedures, 2-3 36-48
calculated for 20 samples (h)
Automation possible proposed (25)
Analytical procedures, 40 30 (gradient)
calculated for 1
chromatogram (min)
Automation yes yes
Reproducibi l i ty
To compare the reproducibility of the two assays we collected
24-hour urine samples from two normal adults (A and B).
During the 24 hours of urine collection, subject A followed a
diet rich in fluids while subject B followed a normal diet. Sample
A was used as a low control, and sample B was considered a
medium control. Galactosyl hydroxylysine was measured by
the method of Moro et al, (21), while deoxypyridinoline was
measured by the method of Kamel et al. with minor modifica-
tions (24). To calculate the intra-assay variation we tested
samples A and B in 4—6 replicates. The test was repeated on
4 different days and the intra-assay variation was calculated as
the mean ± SD of the intra-assay coefficient of variation of
each» day. To calculate the inter-assay variation we tested sample
A and B on 7 sequential days.
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Tab. 5. Galactosyl hydroxylysine and deoxypyridinoline concentration (mean ± standard deviation) and intra-assay and inter-
assay variation of the two measurements
Galaclosyl hydroxylysine Deoxypyridinoline
Infra-assay variation
Sample A
n
Mean ± SD
CV
Sample B
n
Mean ± SD
CV
Infer-assay variation
Sample A
n
Mean ± SD
CV
Sample B
n
Mean ± SD
CV
1.95 ± 0.17μπιο1/1
4.6 ± 1.7%
V
6.07 ± 0.35 μπκ>1/1
4.7 ± 1.5%
1.93 ±0.16μηχ>1/1
8.6%
5.93 ± 0.39 μπιοΐ/ΐ
6.7%
11.3 ±1.54 nmol/1
8.4 ± 4.8%
22.3 ± 2.82 nmol/1
9.2 ± 1.8%
10.23 ± 1.79 nmol/1
17.5%
21.6 ±2.49nmol/I
11.5%
Reproducibility Results
The results are reported in table 5. Galactosyl hy-
droxylysine showed a lower intra-assay variation than
deoxypyridinoline with a coefficient of variation (CV)
ranging from 4.6 ±1.7 (Sample A) to 4.7 ±1.5
(Sample B) for galactosyl hydroxylysine and from 8.4
± 4.8 (Sample A) to 9.2 ± 1.8 (Sample B) for deoxy-
pyridinoline. Similarly, the inter-assay variation was
much lower for galactosyl hydroxylysine than for
deoxypyridinoline. The galactosyl hydroxylysine in-
ter-assay CV ranged from 8.3% (Sample A) to 6.7%
(Sample B), while the deoxypyridinoline inter-assay
CV ranged from 17.5% (Sample A) to 11.5% (Sample
B).
Discussion
Both galactosyl hydroxylysine and deoxypyridinoline
fulfil the requirements for a specific marker for bone
resorption. Both the molecules are, in fact, relatively
specific for bone, none of them is reutilized after the
collagen breakdown and both of them seem to be
excreted unchanged in the urine (9 — 12). All the clin-
ical studies that have compared their clinical perform-
ances have indeed shown that galactosyl hydroxyly-
sine and deoxypyridinoline are highly correlated, have
similar accuracy and discriminatory power in distin-
guishing subjects with altered bone resorption from
normal subjects (18—20). In the present study, the
methods for galactosyl hydroxylysine and deoxypyr-
idinoline determination were compared.
In addition to the similar clinical value of the two
quantities, the analytical procedures for galactosyl
hydroxylysine and deoxypyridinoline also show many
similarities. Both molecules, for example, are meas-
ured by means of an HPLC system and detected by
fluorescence. An immunoenzymatic test has also been
proposed for deoxypyridinoline (22a). However, be-
cause of the high similarity between deoxypyridinoline
and pyridinoline (the other pyridinium crosslink that
is not bone-specific) the immunoenzymatic test re-
sponds to both of these molecules, so that only the
HPLC procedure guarantees the exclusive measure-
ment of deoxypyridinoline.
Methodologically, the methods for galactosyl hydrox-
ylysine and deoxypyridinoline differ mainly in the
preanalytical procedures. Galactosyl hydroxylysine
does not need to be hydrolyzed and extracted since
this molecule is present in free form in the urine (22b).
On the other hand, since galactosyl hydroxylysine is
not fluorescent, it must be derivatized with dansyl
chloride. In contrast, deoxypyridinoline is naturally
fluorescent. However, in urine, almost 50% of this
molecule is in the form of peptides of different mo-
lecular mass (22). For this reason an acid hydrolysis
and an extraction is needed prior to the injection into
the HPLC.
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The need for a hydrolysis and a preextraction in the
measurement of deoxypyridinoline implies two prob-
lems:
1) time consumption,
2) error due to the recovery.
Time
As shown in table 3c, 36-48 hours are needed for
deoxypyridinoline preanalytical procedures (calcu-
lated for 20 samples) while only 2 — 3 hours are needed
for the galactosyl hydroxylysine derivatization (cal-
culated for 20 samples). For this reason, the deter-
mination of deoxypyridinoline as a routine clinical
procedure would require either a full-time technician
or some kind of automation. An automated liquid
solid extraction procedure for the pyridinium cross-
links has been recently proposed and the ability to
extract 60 samples in 9 hours has been claimed by the
authors (25). If confirmed, this procedure may re-
present a significant improvement to this important
inconvenience in the pyridinium crosslinks measure-
ment.
Recovery
The most important problem of pre-extraction, how-
ever, is the risk of error due to variable recovery of
the samples. In our study both the intra-assay and
inter-assay variations of deoxypyridinoline were 50—
100% higher than those shown for galactosyl hy-
droxylysine. These variations were due to the pre-
extraction since the reproducibility for galactosyl hy-
droxylysine and deoxypyridinoline HPLC procedures
were similar (data not shown). An appropriate inter-
nal standard is frequently used to control this impor-
tant source of variation. Recently Colwell et al. (26)
have proposed iso-desmosine as a possible internal
standard for the pyridinium crosslinks extraction,
since this molecule has a different elution time on
HPLC, but behaves like the pyridinium crosslinks
towards the heat and the acid environment (26). Fur-
ther studies are needed to confirm that the use of iso-
desmosine as an internal standard can decrease the
important variation demonstrated so far for the de-
oxypyridinoline HPLC measurement.
As mentioned above, the analytical procedures for
galactosyl hydroxylysine and deoxypyridinoline are
similar. The HPLC analysis of deoxypyridinoline is,
however, more rapid (because of the preextraction),
and isocratic elution conditions can be used. More-
over, the preextraction allows the injection of a purer
sample into the HPLC, and more runs can therefore
be made on the same column for the deoxypyridino-
line measurement. The analytical procedures of both
galactosyl hydroxylysine and deoxypyridinoline can
be easily automated by using an HPLC system with
an autosampler and a computer.
In conclusion we have reviewed our knowledge of
galactosyl hydroxylysine and deoxypyridinoline with
particular emphasis on the practicality and the repro-
ducibility of their measurements, and we have shown
that the major differences between galactosyl
hydroxylysine and deoxypyridinoline assays are the
preanalytical hydrolysis and an extraction, which
must be performed before the deoxypyridinoline as-
say. The deoxypyridinoline measurement conse-
quently requires longer time for its operation, and its
recovery is more variable.
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